Product Pathways - Cell Cycle / Checkpoint
CDK12 Antibody #11973
|11973S||100 µl (10 western blots)||---||In Stock||---|
|11973||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation
Specificity / Sensitivity
CDK12 Antibody recognizes endogenous levels of total CDK12 protein. This antibody also cross-reacts with proteins of unknown origin at 48 and 53 kDa.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val492 of human CDK12 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Western blot analysis of extracts from 293T cells, mock transfected (-) or transfected with a construct expressing Myc/DDK-tagged full-length human CDK12 isoform 2 (hCDK12-Myc/DDK; +), using CDK12 Antibody.
Immunoprecipitation of CDK12 from PC-3 cell extracts using Normal Rabbit IgG #2729 (lane 2) or CDK12 Antibody (lane 3). Lane 1 is 10% input. Western blot analysis was performed using CDK12 Antibody.
Cyclin-dependent kinase 12 (CDK12/CRKRS/CRK7) is composed of a central CTD kinase domain, several proline-rich regions, and several amino-terminal arginine/serine (RS) motifs common to splicing factors (1). CDK12 is ubiquitously expressed and forms a complex with cyclin K that regulates phosphorylation of the C-terminal domain (CTD) of RNA polymerase II (1-4). CDK12 is important for expression of a subset of long genes with high numbers of exons including some regulators of the DNA damage response, such as breast and ovarian cancer type 1 susceptibility protein 1 (BRCA1) and ataxia telangiectasia and Rad3-related (ATR) (3). Depletion of CDK12 results in spontaneous DNA damage and increased sensitivity to DNA damage agents (3). Research studies have shown that CDK12 is recurrently mutated in high-grade ovarian cancer (5,6). In addition, high levels of CDK12 are required to maintain pluripotency of embryonic stem cells (7).
- Ko, T.K. et al. (2001) J Cell Sci 114, 2591-603.
- Bartkowiak, B. et al. (2010) Genes Dev 24, 2303-16.
- Blazek, D. et al. (2011) Genes Dev 25, 2158-72.
- Cheng, S.W. et al. (2012) Mol Cell Biol 32, 4691-704.
- The Cancer Genome Atlas Research Network (2011) Nature 474, 609-15.
- Carter, S.L. et al. (2012) Nat Biotechnol 30, 413-21.
- Dai, Q. et al. (2012) J Biol Chem 287, 25344-52.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.